DGAP-News
Novavax Announces Management Promotions
DGAP-News: Novavax, Inc. /
Novavax Announces Management Promotions
19.06.2014 / 22:22
---------------------------------------------------------------------
GAITHERSBURG, Md., 2014-06-19 22:22 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused
on the discovery, development, and commercialization of recombinant
nanoparticle vaccines and adjuvants, announced today a number of promotions
within its management team.
John A. Herrmann III, J.D. has been named Senior Vice President, General
Counsel and Corporate Secretary. Mr. Herrmann joined Novavax in March 2010 and
is responsible for managing all of Novavax' legal affairs, including its patent
portfolio, transactional and contractual matters, public securities filings,
and attending to all the duties of Corporate Secretary. Mr. Herrmann also works
with the company's senior management team to define and develop corporate
policies and procedures. Prior to joining Novavax, Mr. Herrmann served as
General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic
before it became Ore Pharmaceuticals. Prior to joining Gene Logic, Mr. Herrmann
served as Senior Counsel for Celera Genomics and prior to that as Senior
Corporate Counsel at Baxter Healthcare in its Renal Division. Mr. Herrmann
received his B.A. in Political Science and History from Brown University and
his J.D. from the University of Illinois.
Denise Courbron, M.S., PMP has been named Vice President, Global Program
Management to lead Novavax' program management efforts covering all vaccine
development programs. Ms. Courbron joined Novavax in June 2010 as Executive
Director, Global Program Management and was instrumental in Novavax' being
awarded its $179 million influenza development contract with HHS BARDA in
February 2011. Prior to joining Novavax, Ms. Courbron held positions of
increasing responsibility in a number of companies in the vaccines industry,
including PharmAthene, Intercell USA, Iomai Corporation, PPD, Baxter
BioScience, GloboMax (ICON), and North American Vaccine. Ms. Courbron received
a B.A. in Political Science and Spanish from Western Maryland College
(McDaniel) and an M.S. in Biotechnology Management from the University of
Maryland University College. Ms. Courbron is a certified Project Management
Professional (PMP(TM)).
'I am very pleased to announce the promotions of John and Denise. Their
contributions over the last number of years have been critical to the success
of the company. John has been irreplaceable assisting the management team and
the board to navigate the regulatory, compliance, and corporate governance
requirements of a public company. Denise's long history of experience with
government contracts and project management has been integral to the successful
execution of our contract with HHS BARDA. I look forward to their continued
involvement in the success of the company,' said Stanley C. Erck, President and
CEO.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent diseases.
Additional information about Novavax is available on the company's website,
novavax.com.
CONTACT: Barclay A. PhillipsSVP, Chief Financial Officer and TreasurerNovavax,
Inc.240-268-2000
News Source: NASDAQ OMX
End of Corporate News
---------------------------------------------------------------------
19.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Novavax, Inc.
United States
ISIN: US6700021040
End of News DGAP News-Service
---------------------------------------------------------------------
274476 19.06.2014
Counsel and Corporate Secretary. Mr. Herrmann joined Novavax in March 2010 and
is responsible for managing all of Novavax' legal affairs, including its patent
portfolio, transactional and contractual matters, public securities filings,
and attending to all the duties of Corporate Secretary. Mr. Herrmann also works
with the company's senior management team to define and develop corporate
policies and procedures. Prior to joining Novavax, Mr. Herrmann served as
General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic
before it became Ore Pharmaceuticals. Prior to joining Gene Logic, Mr. Herrmann
served as Senior Counsel for Celera Genomics and prior to that as Senior
Corporate Counsel at Baxter Healthcare in its Renal Division. Mr. Herrmann
received his B.A. in Political Science and History from Brown University and
his J.D. from the University of Illinois.
Denise Courbron, M.S., PMP has been named Vice President, Global Program
Management to lead Novavax' program management efforts covering all vaccine
development programs. Ms. Courbron joined Novavax in June 2010 as Executive
Director, Global Program Management and was instrumental in Novavax' being
awarded its $179 million influenza development contract with HHS BARDA in
February 2011. Prior to joining Novavax, Ms. Courbron held positions of
increasing responsibility in a number of companies in the vaccines industry,
including PharmAthene, Intercell USA, Iomai Corporation, PPD, Baxter
BioScience, GloboMax (ICON), and North American Vaccine. Ms. Courbron received
a B.A. in Political Science and Spanish from Western Maryland College
(McDaniel) and an M.S. in Biotechnology Management from the University of
Maryland University College. Ms. Courbron is a certified Project Management
Professional (PMP(TM)).
'I am very pleased to announce the promotions of John and Denise. Their
contributions over the last number of years have been critical to the success
of the company. John has been irreplaceable assisting the management team and
the board to navigate the regulatory, compliance, and corporate governance
requirements of a public company. Denise's long history of experience with
government contracts and project management has been integral to the successful
execution of our contract with HHS BARDA. I look forward to their continued
involvement in the success of the company,' said Stanley C. Erck, President and
CEO.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent diseases.
Additional information about Novavax is available on the company's website,
novavax.com.
CONTACT: Barclay A. PhillipsSVP, Chief Financial Officer and TreasurerNovavax,
Inc.240-268-2000
News Source: NASDAQ OMX
End of Corporate News
---------------------------------------------------------------------
19.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Novavax, Inc.
United States
ISIN: US6700021040
End of News DGAP News-Service
---------------------------------------------------------------------
274476 19.06.2014
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte